Skip to main content
. Author manuscript; available in PMC: 2019 Mar 18.
Published in final edited form as: J Clin Psychiatry. 2018 Sep 18;79(5):18m12145. doi: 10.4088/JCP.18m12145

Table 4:

Outcomes for Participants with an Adequate Trial of an Effective Medication for PTSD plus Outcomes Measurement (Unweighted)

Agent Fluoxetine Paroxetine Sertraline Topiramate Venlafaxine Pairwise
Differences
n=659 n=328 n=1,376 n=105 n=463
Raw Outcomes
Baseline PCL Score, M (SD) 61.8 (11.8) 62.2 (12.1) 62.0 (11.7) 61.5 (12.6) 62.5 (12.0) No Differences
Change in PCL, M (SD) -6.2 (14.0) -6.2 (15.1) -6.1 (14.1) -6.3 (13.8) -5.0 (13.3) No Differences
5-Point Drop in PCL, % (n) 51.9 (342) 50.9 (167) 50.1 (689) 42.9 (45) 47.9 (222) No Differences
10-Pt. Drop plus Loss of Diagnosis, % (n) 17.6 (116) 20.4 (67) 17.2 (237) 16.2 (17) 13.6 (63) No Differences
Symptom Clusters
Baseline Reexperiencing, M (SD) 17.7 (4.3) 17.8 (4.2) 17.8 (4.1) 17.9 (4.4) 17.9 (4.2) No Differences
Change in Reexperiencing, M (SD) -1.7 (4.8) -1.8 (4.8) -1.6 (4.6) -2.0 (5.1) -1.2 (4.6) No Differences
Baseline Avoidance, M (SD) 7.6 (1.9) 7.8 (1.8) 7.7 (1.9) 7.4 (2.0) 7.6 (2.0) No Differences
Change in Avoidance, M (SD) -0.7 (2.4) -0.9 (2.5) -0.8 (2.4) -0.6 (2.3) -0.6 (2.3) No Differences
Baseline Numbing, M (SD) 17.3 (4.3) 17.0 (4.3) 17.2 (4.3) 16.9 (4.6) 17.5 (4.3) No Differences
Change in Numbing, M (SD) -1.8 (4.8) -1.5 (5.2) -1.8 (5.0) -1.7 (4.9) -1.5 (4.8) No Differences
Baseline Hyperarousal, M (SD) 19.4 (3.9) 19.5 (4.0) 19.4 (3.8) 19.5 (4.1) 19.6 (3.8) No Differences
Change in Hyperarousal, M (SD) -2.0 (4.6) -1.8 (4.8) -1.9 (4.5) -2.1 (4.5) -1.8 (4.3) No Differences
Baseline Sleep, M (SD) 7.4 (1.9) 7.6 (1.9) 7.5 (1.9) 7.4 (2.1) 7.6 (1.9) No Differences
Change in Sleep, M (SD) -0.8 (2.2) -0.9 (2.1) -0.8 (2.1) -0.8 (2.4) -0.6 (2.1) No Differences

Note. PTSD=Posttraumatic Stress Disorder, PCL=PTSD Checklist, M=mean, SD=standard deviation